Ensayo Clínico de Fase 2 con Dosificación Quincenal de Ir... | EligiMed

Ensayo Clínico de Fase 2 con Dosificación Quincenal de Irofulven más Capecitabine en Pacientes con Cáncer de Tiroides Anaplásico o Diferenciado Localmente Avanzado/Metastásico

CompletadoFase 2ClinicalTrials.gov

ID: NCT00124527Tipo: INTERVENTIONALInicio: 31 de mar de 2005Fin estimado: 31 de ago de 2006

Resumen

Irofulven es un agente quimioterapéutico en investigación que está siendo estudiado en una variedad de tumores sólidos. El propósito de este estudio es evaluar la eficacia y la seguridad de la terapia combinada irofulven/capecitabine en pacientes con cáncer de tiroides anaplásico, medular o diferenciado localmente avanzado/metastásico.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

years of age or older.
Cancer of the thyroid confirmed by a biopsy sample. Specific types of thyroid cancer included in this study are anaplastic, differentiated (papillary, follicular, or Hürthle cell), and medullary thyroid cancers.
For patients with differentiated (papillary, follicular, or Hürthle cell) thyroid cancer, no more than 1 prior chemotherapy treatment is allowed.
Measurable disease is required (at least one lesion at least 2 cm in length by conventional computed tomography (CT) techniques or at least 1 cm by spiral CT scan).
Any prior chemotherapy or radiation therapy must be stopped at least 4 weeks before the first dose of study treatment. Prior radioiodine (I131) therapy must be stopped at least 3 (or 6) months before first dose of study treatment (depending on responsiveness to this therapy).
Recovery from any toxic effects of prior chemotherapy, radiation therapy and surgery.
Patients with reproductive potential must use a medically acceptable contraceptive method. Women of childbearing potential must have a negative pregnancy test at screening.

Criterios de exclusión

History of retinopathy.
Serious ongoing medical or psychiatric disorder (as determined by the clinical investigator).
External beam radiation therapy to \>30% of the bone marrow at any time prior to study entry.
Prior treatment with irofulven or capecitabine, or protracted infusion of 5-fluorouracil (5-FU) (infusion duration greater than or equal to 5 days) or other fluoropyrimidines.
Therapeutic doses of coumarin derivatives (warfarin) 14 days prior to receiving the first dose of study treatment or during the study period.
Please note: There are additional criteria that must be met in order to be eligible for this study.

Intervenciones

drug

Irofulven + capecitabine

Ubicaciones

Salta, Argentina

Patrocinadores

PrincipalEisai Inc.

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.